Angiogenesis is an independent prognostic factor in malignant mesothelioma

被引:81
作者
Edwards, JG
Cox, G
Andi, A
Jones, JL
Walker, RA
Waller, DA
O'Byrne, KJ
机构
[1] Univ Leicester, Leicester Royal Infirm, Dept Med Oncol, Leicester LE1 5WW, Leics, England
[2] Glenfield Gen Hosp, Dept Resp Med & Thorac Surg, Leicester LE3 9QP, Leics, England
[3] Univ Leicester, Leicester Royal Infirm, Dept Pathol, Leicester LE1 5WW, Leics, England
关键词
malignant mesothelioma; angiogenesis; prognosis; staging;
D O I
10.1054/bjoc.2001.1997
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Angiogenesis is essential for tumour growth beyond 1 to 2 mm in diameter. The clinical relevance of angiogenesis, as assessed by microvessel density (MVD), is unclear in malignant mesothelioma (MM). Immunohistochemistry was performed on 104 archival, paraffin-embedded, surgically resected MM samples with an anti-CD34 monoclonal antibody, using the Streptavidin-biotin complex immunoperoxidase technique. 93 cases were suitable for microvessel quantification, MVD was obtained from 3 intratumoural hotspots, using a Chalkley eyepiece graticule at x 250 power. MVD was correlated with survival by Kaplna-Meier and log-rank analysis. A stepwise, multivariate Cox model was used to compare MVD with known prognostic factors and the EORTC and CALGB prognostic scoring systems. Overall median survival from the date of diagnosis was 5.0 months. Increasing MVD was a poor prognostic factor in univariate analysis (P = 0.02). Independent indicators of poor prognosis in multivariate analysis were non-epithelial cell type (P = 0.002), performance status > 0 (P = 0.003) and increasing MVD (P = 0.01). In multivariate Cox analysis, MVD contributed independently to the EORTC: (P = 0.006), but not to the CALGB (P = 0. 1), prognostic groups. Angiogenesis, as assessed by MVD, is a poor prognostic factor in MM, independent of other clinicopathological variables and the EORTC prognostic scoring system. Further work is required to assess the prognostic importance of angiogenic regulatory factors in this disease. (C) 2001 Cancer Research Campaign.
引用
收藏
页码:863 / 868
页数:6
相关论文
共 59 条
[1]   Angiogenesis in mesotheliomas - Role of mesothelial cell derived IL-8 [J].
Antony, VB ;
Hott, JW ;
Godbey, SW ;
Holm, K .
CHEST, 1996, 109 (03) :S21-S22
[2]   Malignant vascular tumours of the pleura in "asbestos" workers and endothelial differentiation in malignant mesothelioma [J].
Attanoos, RL ;
Suvarna, SK ;
Rhead, E ;
Stephens, M ;
Locke, TJ ;
Sheppard, MN ;
Pooley, FD ;
Gibbs, AR .
THORAX, 2000, 55 (10) :860-863
[3]   Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology [J].
Banks, RE ;
Forbes, MA ;
Kinsey, SE ;
Stanley, A ;
Ingham, E ;
Walters, C ;
Selby, PJ .
BRITISH JOURNAL OF CANCER, 1998, 77 (06) :956-964
[4]  
Bicknell Roy, 1996, Current Opinion in Oncology, V8, P60, DOI 10.1097/00001622-199601000-00011
[5]   Thalidomide: Current and potential clinical applications [J].
Calabrese, L ;
Fleischer, AB .
AMERICAN JOURNAL OF MEDICINE, 2000, 108 (06) :487-495
[6]  
Chaudhary R, 1999, ANTICANCER RES, V19, P3479
[7]   New paradigms for the treatment of cancer: The role of anti-angiogenesis agents [J].
Cherrington, JM ;
Strawn, LM ;
Shawver, LK .
ADVANCES IN CANCER RESEARCH, VOL 79, 2000, 79 :1-38
[8]  
COX DR, 1972, J R STAT SOC B, V34, P187
[9]   Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer [J].
Cox, G ;
Walker, RA ;
Andi, A ;
Steward, WP ;
O'Byrne, KJ .
LUNG CANCER, 2000, 29 (03) :169-177
[10]   A biological staging model for operable non-small cell lung cancer [J].
Cox, G ;
Jones, JL ;
Andi, A ;
Waller, DA ;
O'Byrne, KJ .
THORAX, 2001, 56 (07) :561-566